VESCO-R®: Peripheral Blood Derived Mesenchymal Stem Cell Therapy in Regenerative Medicine

细胞疗法提供了治疗和治愈严重的未得到满足的医疗需求的机会。BioDivide发现了一种创新的制造技术来开发Vesco-R®-一种从有限的外周血样中提取的自体间充质干细胞(MSCs)的悬浮液。目前最先进的从外周血中分离骨髓间充质干细胞的方法效率很低，而且变化很大。该公司筛选了500个条件，以发展这项突破性技术的基础科学。目前的自体干细胞活组织检查技术需要侵入性的外科手术(例如，在全身麻醉下采集骨髓和脂肪组织)。外周献血是微创的，将克服该行业的重大障碍。BioDivide与Genesis合作，正在寻求Innovate UK的资金，以便将这项技术从试验台转化为市场就绪的制造工艺和治疗产品Vesco-R®。BioDivide设想通过最初验证Vesco-R®治疗兽医肌肉骨骼疾病来改变再生医学，最终目的是将这项技术转化为人类健康。BLIC项目摘要

Cell therapies offer the opportunity to treat and cure serious unmet medical needs. BioDivide has discoveredan innovative manufacturing technology to develop VESCO-R® - a suspension of autologous Mesenchymal StemCells (MSCs) derived from a limited peripheral blood sample. Current state-of-the-art processes to isolate MSCsfrom peripheral blood are highly inefficient and variable. The Company screened >500 conditions to developthe underpinning science for this break-through technology. Current autologous stem cell biopsy techniquesrequire invasive surgical procedures (e.g. bone marrow and adipose tissue harvesting under generalanaesthetic). Peripheral blood donation is minimally invasive and would overcome significant barriers to theindustry. BioDivide, in collaboration with Genesis, is seeking Innovate UK Funding to enable the translation ofthis technology from the bench to a market-ready manufacturing process and the therapeutic product, VESCO-R®. BioDivide envisions transforming regenerative medicine by initially validating VESCO-R® for musculoskeletaldisorders in veterinary medicine with the ultimate aim to translate this technology to human health.blic Project Summary